leisure time -WSS

leisure time

author：comprehensive 2025-10-01 01:49:46 - browse：8949

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

leisure time

WSS

Kaiser's Risant Health gobbled up Geisinger. Who is next?

See how much Covid

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

A virus, fished out of a lake, may have saved a man’s life

Ultragenyx gene therapy for rare liver ailment succeeds in late

Senate panel eyes new effort on drug shortages

hotspot

leisure time

focus

The cancer drug shortage isn’t new — and neither are the solutions

Kaiser's Risant Health gobbled up Geisinger. Who is next?

The high cost of giving birth even with insurance

Innovation in antibiotics is ailing. 'Brain drain' may kill it

New air purifier tech could be key to improving indoor air quality

ASCO: AstraZeneca says CAR

Medical leaders decry Supreme Court decision on affirmative action

Shifting the focus from loneliness to social health

Drug repurposing or repositioning? The language matters

VC firm General Catalyst wants to buy a health system

knowledge

A Q&A with the global head of Boehringer Ingelheim's innovation unit

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Physician executives need more than on

Let's speed up science by embracing open access publishing

Colorectal cancer study finds potential in overlooked immune cell

When women are denied an abortion, their children fare worse than peers

knowledge

hotspot

leisure time

explore